Biogen Inc.

Biogen Inc. is a global biotechnology company focused on discovering, developing, and commercializing therapies for serious neurological, neurodegenerative, and rare diseases. Headquartered in Cambridge, Massachusetts, Biogen concentrates its portfolio on conditions such as multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis, and other complex immunological and neuromuscular disorders. The company markets a broad range of branded medicines, including multiple sclerosis treatments like Tecfidera, Vumerity, Avonex, Plegridy, Tysabri, and Fampyra, as well as Spinraza for spinal muscular atrophy and therapies such as Qalsody and Skyclarys for specific rare neurological indications. Biogen also participates in the biosimilars market with products like Flixabi, Imraldi, and Benepali, expanding access to biologic therapies. Operating as a single business segment, Biogen generates revenue from the discovery, development, and commercialization of these advanced therapies, serving patients across the Americas, Europe, Asia, and additional international markets.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Mr. Christopher A. Viehbacher

Employees

7,500

Headquarters

Cambridge, MA, United States

Website

www.biogen.com